Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines

Annals of Surgical Oncology

Volumn 18, Issue 2, 2011, Pages 371-379

  Motoi, Fuyuhiko ^a   Rikiyama, Toshiki ^a   Katayose, Yu ^a   Egawa, Shin Ichi ^a   Unno, Michiaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIGEN 19-9; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; LIVER METASTASIS; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS RESECTION; PORTAL VEIN; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79951557551     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1311-x     Document Type: Article

References (28)

1. JP Neoptolemos DD Stocken JA Dunn, et al. 2001 European Study Group for Pancreatic Cancer. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial Ann Surg 234 758 768 1:STN:280: DC%2BD38%2FlvFSqsg%3D%3D 11729382 (Pubitemid 33117196)
2. JM Winter JL Cameron KA Campbell, et al. 2006 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience J Gastrointest Surg. 10 1199 1211 17114007 (Pubitemid 44781200)
3. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst. 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
4. CC Jaffe 2006 Measures of response: RECIST, WHO, and new alternatives J Clin Oncol. 24 3245 3251 16829648 (Pubitemid 46622065)
5. AE Ring IE Smith S Ashley, et al. 2004 Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer Br J Cancer. 91 2012 2017 1:CAS:528:DC%2BD2cXhtVOjsLbL 15558072 (Pubitemid 40128767)
6. PM Schneider SE Baldus R Metzger, et al. 2005 Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification Ann Surg. 242 684 692 16244542 (Pubitemid 41567124)
7. F Huguet N Girard C Séblain-El Guerche, et al. 2009 Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review J Clin Oncol. 27 2269 2277 1:CAS:528: DC%2BD1MXlvFOgs7g%3D 19307501
8. HA Burris III MJ Moore J Andersen, et al. 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol. 15 2403 2413 1:CAS:528:DyaK2sXlsFKksLY%3D 9196156 (Pubitemid 27251144)
9. G Cwik G Wallner T Skoczylas, et al. 2006 Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions Arch Surg. 141 968 974 17043274
10. A DelMaschio A Vanzulli S Sironi, et al. 1991 Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy Radiology. 178 95 99 1:STN:280:DyaK3M%2FnsFSitg%3D%3D 1984331
11. F Safi W Schlosser G Kolb, et al. 1997 Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms J Gastrointest Surg. 1 106 112 1:STN:280:DC%2BD28nhslSguw%3D%3D 9834336 (Pubitemid 127433827)
12. KS Goonetilleke AK Siriwardena 2007 Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer Eur J Surg Oncol. 33 266 270 1:STN:280:DC%2BD2s7pvV2mtA%3D%3D 17097848 (Pubitemid 46488663)
13. O Micke F Bruns U Schäfer, et al. 2003 CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy Anticancer Res. 23 835 840 1:CAS:528: DC%2BD3sXltlGgurg%3D 12820309 (Pubitemid 36750881)
14. O Micke F Bruns R Kurowski, et al. 2003 Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy Int J Radiat Oncol Biol Phys. 57 90 97 1:CAS:528:DC%2BD3sXlvFGktbo%3D 12909220 (Pubitemid 36959743)
15. C Ziske C Schlie M Gorschlüter, et al. 2003 Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine Br J Cancer. 89 1413 1417 1:CAS:528:DC%2BD3sXotFeksL8%3D 14562009 (Pubitemid 37386593)
16. NR Maisey AR Norman A Hill, et al. 2005 CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials Br J Cancer. 93 740 743 1:CAS:528:DC%2BD2MXhtVeksbvE 16175188 (Pubitemid 41486431)
17. CR Ferrone DM Finkelstein SP Thayer, et al. 2006 Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma J Clin Oncol. 24 2897 2902 1:CAS:528:DC%2BD28XntV2gs7o%3D 16782929 (Pubitemid 46630592)
18. V Hess B Glimelius P Grawe, et al. 2008 CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial Lancet Oncol. 9 132 138 1:CAS:528: DC%2BD1cXhsVOnu7Y%3D 18249033
19. Y Nakai T Kawabe H Isayama, et al. 2008 CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer Oncology. 75 120 126 1:CAS:528:DC%2BD1cXhtFKgsrfE 18784438
20. M Reni S Cereda G Balzano, et al. 2009 Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma Cancer. 115 2630 2639 1:CAS:528:DC%2BD1MXotFOgsr0%3D 19353729
21. A Nakao T Fujii H Sugimoto, et al. 2006 Oncological problems in pancreatic cancer surgery World J Gastroenterol. 12 4466 4472 16874856 (Pubitemid 44256331)
22. S Kawa H Oguchi T Kobayashi, et al. 1991 Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype Br J Cancer. 64 899 902 1:STN:280:DyaK38%2FjtV2ltQ%3D%3D 1931612
23. S Matsuno S Egawa S Fukuyama, et al. 2004 Pancreatic Cancer Registry in Japan: 20 years of experience Pancreas. 28 219 230 15084961 (Pubitemid 38437313)
24. TJ Kinsella Y Seo J Willis, et al. 2008 The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer Am J Clin Oncol. 31 446 453 1:CAS:528:DC%2BD1cXhtF2ktbfE 18838880
25. RC Montgomery JP Hoffman LB Riley, et al. 1997 Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas Ann Surg Oncol. 4 551 556 1:STN:280:DyaK1c%2Fjtlyruw%3D%3D 9367020 (Pubitemid 127725501)
26. DK Chang AL Johns ND Merrett, et al. 2009 Margin clearance and outcome in resected pancreatic cancer J Clin Oncol. 27 2855 2862 19398572
27. HJ Kim MH Kim SJ Myung, et al. 1999 A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve Am J Gastroenterol. 94 1941 1946 1:STN:280:DyaK1Mzjt1yqtA%3D%3D 10406263
28. K Inoue T Hiraoka K Kanemitsu, et al. 2006 Onset of liver metastasis after histologically curative resection of pancreatic cancer Surg Today. 36 252 256 16493535 (Pubitemid 43288719)